- Home
- PLUT vs OVID Comparison
PLUT vs OVID Comparison
Compare PLUT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUT
- OVID
- Stock Information
- Founded
- PLUT 2018
- OVID 2014
- Country
- PLUT Hong Kong
- OVID United States
- Employees
- PLUT N/A
- OVID N/A
- Industry
- PLUT
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- PLUT
- OVID Health Care
- Exchange
- PLUT NYSE
- OVID Nasdaq
- Market Cap
- PLUT 42.9M
- OVID 47.1M
- IPO Year
- PLUT 2025
- OVID 2017
- Fundamental
- Price
- PLUT $2.55
- OVID $0.38
- Analyst Decision
- PLUT
- OVID Strong Buy
- Analyst Count
- PLUT 0
- OVID 6
- Target Price
- PLUT N/A
- OVID $3.03
- AVG Volume (30 Days)
- PLUT 104.0K
- OVID 289.9K
- Earning Date
- PLUT 01-01-0001
- OVID 03-11-2025
- Dividend Yield
- PLUT N/A
- OVID N/A
- EPS Growth
- PLUT N/A
- OVID N/A
- EPS
- PLUT N/A
- OVID N/A
- Revenue
- PLUT $952,965.00
- OVID $566,000.00
- Revenue This Year
- PLUT N/A
- OVID N/A
- Revenue Next Year
- PLUT N/A
- OVID N/A
- P/E Ratio
- PLUT N/A
- OVID N/A
- Revenue Growth
- PLUT N/A
- OVID 44.39
- 52 Week Low
- PLUT $2.26
- OVID $0.35
- 52 Week High
- PLUT $4.22
- OVID $3.45
- Technical
- Relative Strength Index (RSI)
- PLUT N/A
- OVID 37.03
- Support Level
- PLUT N/A
- OVID $0.42
- Resistance Level
- PLUT N/A
- OVID $0.49
- Average True Range (ATR)
- PLUT 0.00
- OVID 0.05
- MACD
- PLUT 0.00
- OVID 0.01
- Stochastic Oscillator
- PLUT 0.00
- OVID 17.20
About PLUT PLUTUS FINANCIAL GROUP LIMITED
Plutus Financial Group Ltd provides financial services. It mainly offers (i) securities dealings and brokerage services (ii) margin financing services and (iii) underwriting and placing services.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.